Why in News The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has crossed a landmark — with 18,000+ Jan Aushadhi Kendras operational and cumulative citizen savings of an estimated ₹38,000 crore, it is now one of the world’s largest generic medicine distribution networks. With medicines priced 50–80% below branded equivalents, the scheme directly addresses catastrophic health expenditure faced by India’s poor.
The Branded vs Generic Drug Paradox
India is the “pharmacy of the world” — supplying 20% of global generic medicines by volume and exporting ~₹2.5 lakh crore worth of pharmaceuticals annually. Yet domestically, patients routinely pay 10–20 times more for branded medicines than equivalent generics with identical active ingredients.
| Drug Example | Branded Price (approx.) | Generic Equivalent | Savings |
|---|---|---|---|
| Metformin 500mg (30 tabs) | ₹120–180 | ₹15–25 | ~85% |
| Atorvastatin 10mg (30 tabs) | ₹150–200 | ₹20–30 | ~85% |
| Amoxicillin 500mg (10 caps) | ₹80–120 | ₹15–25 | ~80% |
| Paracetamol 500mg (10 tabs) | ₹20–30 | ₹3–5 | ~80% |
Why this paradox exists:
- Doctors often prescribe by brand name (industry marketing influence)
- Pharmacies earn higher margins on branded drugs
- Patient perception that branded = better quality
- Weak enforcement of generic prescribing norms
Jan Aushadhi Scheme — Overview
| Parameter | Details |
|---|---|
| Full name | Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) |
| Launched | 2008 (revamped 2015 under new framework) |
| Nodal agency | Bureau of Pharma PSUs of India (BPPI) |
| Under | Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers |
| Kendras operational | 18,000+ (target: 25,000 by March 2026) |
| Medicine portfolio | 2,110 medicines + 293 surgical devices |
| Therapeutic categories | 29 (cardiovascular, anti-infectives, anti-diabetic, etc.) |
| Pricing | 50–80% cheaper than branded equivalents |
| Cumulative sales (MRP) | ₹7,700 crore by June 2025 |
| Citizen savings (estimated) | ₹38,000 crore |
How the Jan Aushadhi Supply Chain Works
Central procurement by BPPI
↓
Sourced from Central PSU pharma companies
(HOCL, RDPL, KAPL, BCPL + WHO-GMP certified private manufacturers)
↓
NABL-accredited quality testing labs
↓
Central warehouses (Gurugram HQ + regional warehouses)
↓
Jan Aushadhi Kendras (retail outlets)
↓
Patient gets medicine at MRP printed on pack
Quality assurance mechanisms:
- All medicines sourced only from WHO-GMP (Good Manufacturing Practices) certified plants
- Third-party testing at NABL-accredited laboratories
- Barcode-based inventory management
- Real-time sales data via PMBJP software portal
Suvidha Sanitary Pad — The ₹1 Revolution
One of the scheme’s most impactful products is the “Suvidha” oxo-biodegradable sanitary napkin, priced at just ₹1 per pad (pack of 4 for ₹4).
| Aspect | Detail |
|---|---|
| Price | ₹1/pad (vs ₹8–12/pad in branded market) |
| Type | Oxo-biodegradable (environmentally safer) |
| Brand | Suvidha (PMBJP) |
| Impact | Improved menstrual hygiene access for rural, tribal, and urban poor women |
| Connection | Aligns with Swachh Bharat Mission + National Menstrual Hygiene Policy |
Challenges and Limitations
| Challenge | Details |
|---|---|
| Doctor prescribing behaviour | Most doctors prescribe by brand; MCI/NMC guidelines on generic prescribing are weakly enforced |
| Urban Kendra viability | High real estate costs; branded pharmacy competition makes Jan Aushadhi outlets less viable in cities |
| Awareness gap | Large segments of population unaware of Jan Aushadhi Kendras’ location and product range |
| Stock-outs | Certain medicines unavailable intermittently due to supply chain gaps |
| Perception barrier | Lingering public belief that cheaper = lower quality despite identical formulations |
Policy Connections — UPSC Linkages
Universal Health Coverage (UHC) and SDG 3
High out-of-pocket (OOP) expenditure on medicines is a leading cause of catastrophic health expenditure — defined as spending more than 10% of household income on health. India’s OOP is ~48% of total health expenditure (among the highest in Asia). Affordable medicines directly reduce this burden.
TRIPS Flexibilities and Pharmaceutical Access
India’s Patents Act 2005 Section 3(d) — prevents ever-greening of pharmaceutical patents — is a key tool that enables generic drug manufacturing. This supports both the export-oriented pharma industry and domestic schemes like PMBJP.
National Medical Commission (NMC) and Generic Prescribing
NMC regulations require doctors to prescribe by generic name (INN — International Non-proprietary Name) rather than brand name. Enforcement remains weak, but PMBJP gains when generics are prescribed.
UPSC Angle
- GS2 — Social Justice / Health: Universal health coverage, catastrophic health expenditure, OOP reduction, menstrual hygiene (Suvidha pad).
- GS3 — Economy: Pharmaceutical sector (India as pharmacy of the world), PLI for pharma, generic vs branded drug market.
- GS2 — Governance: BPPI as nodal agency, role of DoPh, NMC regulation of prescribing.
- Mains Q: “Jan Aushadhi is a supply-side solution to a demand-side problem. Critically examine.”
Prelims-ready facts:
- PMBJP nodal agency: BPPI (Bureau of Pharma PSUs of India)
- Kendras: 18,000+ (target 25,000 by March 2026)
- Portfolio: 2,110 medicines + 293 surgical devices; 29 therapeutic categories
- Citizen savings: ~₹38,000 crore estimated
- Suvidha pad: ₹1/pad (oxo-biodegradable)
- Quality standard: WHO-GMP manufacturing + NABL-accredited testing
Facts Corner
- PMBJP: Launched 2008; revamped 2015; nodal agency — BPPI under Dept. of Pharmaceuticals
- Network: 18,000+ Jan Aushadhi Kendras; target 25,000 by March 2026
- Portfolio: 2,110 medicines + 293 surgical devices across 29 therapeutic categories
- Price advantage: 50–80% cheaper than branded equivalents
- Cumulative MRP sales: ₹7,700 crore by June 2025
- Citizen savings: ~₹38,000 crore estimated
- Suvidha sanitary pad: ₹1/pad — oxo-biodegradable; flagship product for menstrual hygiene
- Quality: WHO-GMP manufacturing + NABL-accredited third-party testing
- OOP expenditure: India at ~48% of total health expenditure — among Asia’s highest
- TRIPS Section 3(d): India’s Patents Act clause preventing ever-greening; enables generic manufacturing
